AbCellera Biologics (ABCL) Revenue (2020 - 2023)
Historic Revenue for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to $9.2 million.
- AbCellera Biologics' Revenue fell 5739.61% to $9.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was $9.2 million, marking a year-over-year decrease of 8178.48%. This contributed to the annual value of $28.8 million for FY2024, which is 2417.36% down from last year.
- According to the latest figures from Q4 2023, AbCellera Biologics' Revenue is $9.2 million, which was down 5739.61% from $6.6 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Revenue ranged from a high of $316.6 million in Q1 2022 and a low of $4.7 million during Q1 2020
- For the 4-year period, AbCellera Biologics' Revenue averaged around $70.7 million, with its median value being $16.9 million (2022).
- Per our database at Business Quant, AbCellera Biologics' Revenue soared by 425346.79% in 2021 and then plummeted by 9614.89% in 2023.
- Quarter analysis of 4 years shows AbCellera Biologics' Revenue stood at $207.9 million in 2020, then tumbled by 32.98% to $139.3 million in 2021, then plummeted by 84.54% to $21.5 million in 2022, then plummeted by 57.4% to $9.2 million in 2023.
- Its Revenue was $9.2 million in Q4 2023, compared to $6.6 million in Q3 2023 and $10.1 million in Q2 2023.